Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.915 -0.125 (-3.09%)
Streaming Delayed Price Updated: 2:34 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
If you decide to invest in this company, it's probably best to start small. 
Via The Motley Fool
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases. 
Via Stocktwits
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
Via Chartmill
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized. 
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
Iovance (IOVA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗
The company is studying its approved drug for many other indications. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
IOVA Shares Jump 8% — What’s Retail Expecting? ↗
Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. 
Via Stocktwits
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
Don't get too excited about their prospects. 
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
This juicy upside potential comes at a cost. 
Via The Motley Fool
News headline image
Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
Iovance (IOVA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
News headline image
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗
Iovance has a long way to go to get to a break-even point, but the company has been showing progress. 
Via The Motley Fool
News headline image
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
Wall Street may be overestimating these companies' potential. 
Via The Motley Fool
News headline image
Top movers in Thursday's session ↗
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.